Why Become an ADAA Sponsor?
- Interested in sponsorship opportunities? Please contact Katie Russo: [email protected]
- **Please note that exhibit space is now sold out! Please contact Katie Russo [email protected] if you would like to convert a potential exhibit sponsorship to a different type of conference support opportunity.\
- For conference advertising opportunities please contact Lise Bram: [email protected]
Rogers Behavioral Health is a leading provider of evidence-based mental health services nationwide. Rogers provides inpatient, residential, and outpatient care for adults, children, and teens with depression and mood disorders, eating disorders, addiction, OCD and anxiety disorders, PTSD, and mental health disorders in kids with autism. Learn more at rogersbh.org.
About Sage Therapeutics
Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner. For more information, please visit www.sagerx.com.
Founded in 1978, Biogen is a leading global biotechnology company that has pioneered multiple breakthrough innovations, including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, neuropsychiatry, specialized immunology and rare diseases and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world.
We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - Twitter, LinkedIn, Facebook, YouTube.
VistaGen Therapeutics is developing new generation medications for multiple mental health and neurology markets where current treatments are inadequate to meet the growing needs of millions of patients worldwide. Looking beyond the limitations of current treatments for anxiety, depression and suicidal ideation, VistaGen's pipeline includes three differentiated, late-stage new drug candidates, AV-101, PH10 and PH94B, each with an exceptional safety profile and fast-acting potential to treat these debilitating diseases and disorders. VistaGen is committed to improving mental health by raising awareness of the conditions that affect the daily lives of millions of patients around the world and to introducing novel treatment alternatives into inadequate treatment paradigm
Established in 1987, the American Foundation for Suicide Prevention is dedicated to saving lives and bringing hope to those affected by suicide. AFSP creates a culture that’s smart about mental health through education and community programs, develops suicide prevention through research and advocacy, and provides support for those affected by suicide.
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism & Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension.
Learn more at www.janssen.com. Follow us at www.twitter.com/JanssenUS and www.twitter.com/JanssenGlobal. Janssen Pharmaceuticals, Inc. is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
McLean Hospital offers exceptional care for children and adults who are living with depression and anxiety, including OCD. A top-rated hospital by U.S. News & World Report, compassionate care at McLean is provided using evidence-based treatment methods through short-term inpatient, diagnostically-specific residential, day treatment and intensive outpatient programs.
Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for central nervous system (CNS) conditions that have limited treatment options. Through development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions. At Axsome, we are intensely committed to developing products that meaningfully improve the lives of patients and provide additional therapeutic options for physicians.
At Cohen Veterans Network, we seek to improve the quality of life for veterans, including those from the National Guard and Reserves, active duty, and their families. CVN works to strengthen mental health outcomes and complement existing support. Our vision is to ensure that every veteran, active duty service member, and family member is able to obtain access to high-quality care that enables them to lead fulfilling and productive lives.
Intra-Cellular Therapies is a biopharmaceutical company founded on Dr. Paul Greengard’s Nobel Prize-winning research that uncovered how therapies affect the inner-working of cells in the body.
We leverage this intracellular approach to deliver treatments that will be transformative for people living with complex psychiatric and neurologic diseases. We celebrate science, welcome curiosity, expect collaboration and demand integrity and respect in all we do, create and deliver.
Mountain Valley Treatment Center provides clinically intensive residential treatment to teenagers and emerging adults struggling with severe Anxiety, Obsessive Compulsive, and related disorders. Mountain Valley is committed to providing empirically supported treatment with a specific focus on Exposure based Cognitive Behavioral Therapy.
Sheppard Pratt—the nation’s largest private, nonprofit mental health provider, consistently ranked among the top psychiatric hospitals by U.S. News & World Report—is home to highly specialized programs: The Retreat, The LifeLaunch, Comprehensive Outpatient Psychiatric Evaluation Service, Center for Eating Disorders, Center for Autism, and Center for OCD and Anxiety.
Skyland Trail is a nationally recognized nonprofit mental health treatment organization located in Atlanta offering evidence-based primary psychiatric residential treatment and day treatment programs for adults and adolescents.
At Sunovion, we are advancing therapies to tackle some of the most challenging psychiatric and neurological disorders that impact the lives of millions of people worldwide. As a patient-centered company, we focus on improving the quality of life for those living with serious CNS conditions. Within a decade, we have introduced several new treatment options and will continue expanding our portfolio to enable better outcomes for those we serve. Innovation today, healthier tomorrows.
CBTeam is devoted to the treatment of OCD and Anxiety Disorders. Our primary treatment consists of Exposure and Response Prevention, more generally referred to as ERP or Exposure Therapy.
This is a treatment that builds confidence and reduces stress and anxiety by teaching someone how to have an effective relationship with anxiety.
Elsevier is the proud publisher of Journal of Mood & Anxiety Disorders™, the new open access official publication of the Anxiety & Depression Association of America to be launched in 2023. Our ScienceDirect platform combines authoritative full-text scientific, technical and health publications with smart, intuitive functionality so that users can stay informed in their fields and can work more effectively and efficiently. Visit Elsevier.com to learn more about us and our journals.
Neumora Therapeutics, Inc. is a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience. Neumora is redefining neuroscience research and development with a data-driven precision neuroscience platform to cut through brain disease heterogeneity to match the right patient populations to targeted therapeutics. Neumora is relentless in its commitment to discovering, developing and commercializing targeted therapies for people living with brain diseases. Neumora has operations in the Greater Boston Area and South San Francisco. For additional information, please visit www.neumoratx.com and follow us on Twitter: @NeumoraTx
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. The lead clinical program, RELIANCE, is studying REL-1017 for MDD in ongoing Phase 3 trials. REL-1017 is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission adults.